The Society for Immunotherapy of Cancer (SITC) Fellowships, funded via the SITC Forward Fund, award $100,000 USD one-year grants to early-career MD, PhD, or MD/PhD investigators advancing cancer immunotherapy research. Since 2014, over $6 million has been invested to cultivate the next generation of immuno-oncology experts.
Eligibility Criteria:
-
Membership: Must be a SITC Active Member in good standing—or have applied for membership—by the LOI deadline.
-
Career Stage: Early-career investigators (MD, PhD, or MD/PhD) pursuing clinical or translational immunotherapy research.
-
Fellowship Tracks:
-
Genmab Translational Fellowship: Focus on DLBCL, FL, or CLL immunotherapy.
-
Merck Clinical Fellowship: Clinical immunotherapy research.
-
SITC Cancer Immunotherapy Fellowship: Broad clinical or translational immunotherapy studies.
-
-
Mentorship: Applicants must secure a Mentor’s Statement of Support.
Funding Details:
-
Amount: $100,000 USD per fellowship (Genmab, Merck, and SITC tracks).
-
Term: One year of salary support, research expenses, and mentorship.
Deadline & Application Process:
-
LOI Deadline: March 12, 2025 (Stage 1).
-
Stage 1 (LOI): Submit application form, project abstract, applicant biosketch, and Mentor’s Statement of Support.
-
Stage 2 (Full Application): Invited applicants provide statement of purpose, mentor’s biosketch, institutional support letter, detailed research plan and budget, facility description, and two references.
-
Notification: Stage 2 invitations and final decisions follow per SITC’s published timeline.
Where to Go for Further Information:
-
Fellowship Guidelines & Application: Download the 2025 SITC Fellowship Guidelines PDF from the SITC website.
-
Membership/Renewal: Join or renew.
-
Questions: [email protected] or [email protected] (for philanthropic inquiries).